Breaking News

Perrigo Acquires Rosemont Pharma

February 11, 2013

Expands liquid categories and Rx medicines, broadens market access

Perrigo has completed the acquisition of Rosemont Pharmaceuticals, based in Leeds, UK, for approximately $283 million in cash. Rosemont is a specialty and generic pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations, with a portfolio of more than 90 products. Rosemont's sales were approximately $60 million in 2012.
 
Perrigo chairman, president and chief executive officer Joseph C. Papa said, "We continue to focus on expanding our international footprint and view the acquisition of Rosemont as an opportunistic next step given our existing presence in the UK. Similar to Perrigo's position in the niche U.S. extended topical generic prescription market, Rosemont is the #1 player in the niche specialty U.K. oral liquid formulations market. We are excited to announce the acquisition of Rosemont and welcome its more than 200 employees to the Perrigo family. This transaction represents another step forward executing our strategy to make quality healthcare products more affordable for consumers around the world."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important